Business Wire

Dr Catarina Edfjäll joins Arex Advisor.

Share

Dr Catarina Edfjäll joins Arex as Senior Advisor in Basel, Switzerland. She will strengthen the company’s expertise and capabilities within global pharmaceutical development leadership in areas such as regulatory affairs strategy, portfolio management, orphan designations, new product development and registration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220424005002/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr. Catarina Edfjäll joins Arex Advisor (Photo: Business Wire)

Dr Edfjäll received her education in Biology and Biotechnology and was awarded a PhD degree in Biochemistry at the University of Basel in 1996.

Throughout her career Catarina has been building and leading European and Global Regulatory Affairs teams in the pharmaceutical sector. Over the years she has been responsible for the marketing authorization of more than 20 medicinal products and new indications, including for cancers and rare diseases, in over 50 countries. Most recently, Dr Edfjäll held the position of Vice President and Head of Global Regulatory Affairs at CSL Behring.

Linda Thunell, CEO of Arex Advisor: “We warmly welcome Catarina to the team. Her long-standing and extensive experience from senior global regulatory roles enables us to expand the boundaries of how we can help our partners achieve their ambitions Europe-wide.”

About Arex Advisor:

We are committed, in heart and mind, to the development and commercialization of important new medicines. With our experience and dedication we are able to help our clients stay one step ahead in pharmaceutical project planning and development. This can ease the way towards successful commercialization in Europe and globally and, ultimately, improve the lives of patients.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Linda Thunell
contact@arexadvisor.com
arexadvisor.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LG Chem Develops Advanced Plastic Product to Prevent Thermal Runaway in EV Batteries16.5.2022 07:00:00 CEST | Press release

LG Chem (KRX: 051910) today announced that it has developed a new plastic product for battery application that is capable of preventing the spread of flame in batteries, delivering the longest fire-resistance performance in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220515005002/en/ LG Chem has developed an advanced plastic product which prevents thermal runaway in EV batteries. (Photo: Business Wire) LG Chem’s flame-retardant engineering plastic product is able to prevent the spread of flames, thanks to the company’s proprietary technology and manufacturing methods. The new advanced flame barrier product created by LG Chem is a highly functional engineering plastic product made from various composites including polyphenylene oxide (PPO) and polyamide (PA) resin. “We are proud to present this new product, a significant milestone for us after more than 10 years of dedicated research to deliver innovation for ou

Envoy Gateway Makes Using Envoy Proxy Easier for Developers and Reverses Fragmentation16.5.2022 06:01:00 CEST | Press release

Members of the steering group for Envoy Gateway (EG), including Envoy creator Matt Klein and representatives from Ambassador Labs, Fidelity Investments, Tetrate, and VMware, Inc., today announced their joint commitment to the project, which launched today at KubeCon + CloudNativeCon, Europe 2022, under the auspices of the Cloud Native Computing Foundation® (CNCF®). Envoy Gateway is a new effort within the Envoy proxy open source project to simplify Envoy use in cloud-native application development. Envoy Gateway will reduce existing, redundant efforts around Envoy and make it much easier for application developers to use Envoy as a basic API gateway “out of the box” and as a Kubernetes Ingress controller. Exposing a simplified set of APIs, and implementing the Kubernetes Gateway API, EG makes it easier to extend Envoy. Developers will now have a cost-free, unfettered way to provide external access to their work in progress. At the same time, Envoy Gateway will not replace API managemen

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis15.5.2022 18:41:00 CEST | Press release

Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was published in The New England Journal of Medicine (NEJM). The promising 12-week data that showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF) will also be presented at the American Thoracic Society (ATS) International Conference Breaking News session on May 16 in San Francisco.1 “These encouraging, early data showed that treatment with BI 1015550 slowed the rate of lung function decline in patients who were not on approved antifibrotics, as well as those who were taking existing antifibrotic therapy,” commented Luca Richeldi, Professor of Respiratory Medicine at the Università Cattolica del Sacro Cuore in Rome, Italy, and the Principal Investigator on the trial. The primary endpoint of the trial was the change from baseline in forced vital capacity (FVC) – meaning the maximum amount of air (m

REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202213.5.2022 13:24:00 CEST | Press release

Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2022. Since the beginning of the year, the Group has recorded a consolidated turnover amounting to €440.9 million, an increase of 25.1% compared to the corresponding data for 2021. All indicators are positive for the period. In the first quarter of 2022 the consolidated EBITDA was €70.9 million compared to €59.6 million in 2021, equal to 16.1% of the turnover. EBIT, from January to March, was €57.7 million (€47.9 million in 2021), and is equal to 13.1% of the turnover. The profit before tax, from January to March, was €59.4 million (€47.6 million in 2021), equal to 13.5% of the turnover. The net financial position of the Group on 31 March 2022 is also positive by 279.7 million. The net financial position on 31 December 2021 was positive for €193.2 million. The comparison with the figures recorded at the end of March 2020 is even sharper. Over the past 24 months, first-quarter turnover inc

Tecnotree Launches Total Digital Transformation Suite for Enterprises and Customers of MTN Ghana13.5.2022 12:00:00 CEST | Press release

Tecnotree, a Finnish-based global provider of digital transformation solutions for Communication Service Providers (CSPs) and Digital Service Providers (DSPs), announced the launch of its digital transformation stack, for enterprise and consumer businesses with MTN Ghana, one of the leading telecommunications service providers in Ghana with over 25.3 million subscribers. This transformation for B2B and B2C empowers the operator with rapid response capabilities, allowing it to meet its enterprise market demand and deliver augmented customer experiences at a reduced cost. Tecnotree’s Digital Transformation Suite 5 product stack is completely TM Forum compliant and deploys a micro-services-based architecture with built-in features for price approvals and overriding, on-boarding and monitoring of cash flow orders via the Customer 360 view, enabling self-care features for consumers and enterprises to manage their accounts, monitor onboarding, raise tickets and service requests. In addition,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom